"Safe" PFAS Replacements Shown To Have Toxic Effects
Complete the form below to unlock access to ALL audio articles.
Per- and polyfluoroalkyl substances (PFASs), a class of chemicals, are featured with hydrophobicity, lipophobicity, and thermal stability. Since the 1950s, they have been widely used in a wide range of industrial and consumer products.
However, PFASs' bioaccumulation and toxicity in wildlife and humans restrict their applications. Next-generation PFASs such as perfluoroether carboxylic acids (PFECAs) are needed to replace conventional PFASs.
Recently, a research group led by Prof. XU Guowang from the Dalian Institute of Chemical Physics (DICP) of the Chinese Academy of Sciences (CAS), in collaboration with Prof. WANG Jianshe from Yantai University, has revealed the toxic effects of PFECAs to mice.
This study was published in Journal of Hazardous Materials on Jan. 20.
The researchers explored the effects of PFECAs on mice based on their long-term exposure to environmentally relevant doses of perfluoro-3,5,7,9,11-pentaoxadodecanoic acid (PFO5DoDA), and revealed that PFECAs exposure suppressed many cellular stress signals and resulted in hepatomegaly.
They found that PFO5DoDA acted as an agonist of the peroxisome proliferator-activated receptor (PPAR) in vitro and modulated PPAR-dependent gene expression in the liver. In addition, PFECAs had an inhibitory effect on the glucocorticoid receptor (GR), which might contribute to suppression of stress signals. GR suppression induced by PFECAs was not found in conventional perfluorooctanoic acid (PFOA).
Through liver metabolomics analysis, the researchers found that PFO5DoDA induced changes in both GR and PPAR signals remodeled hepatic metabolic profiles, including decreased fatty acids and amino acids and increased β-oxidation.
"Our work highlights the potential risk of PFECAs to human and wildlife health," said Dr. LIU Xinyu, corresponding author of this study.
Reference: Wang C, Fu H, Yang J, et al. PFO5DoDA disrupts hepatic homeostasis primarily through glucocorticoid signaling inhibition. J Hazard Mater. 2023;447:130831. doi: 10.1016/j.jhazmat.2023.130831
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.